ISARNA Therapeutics GmbH

- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 1998-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
- Conditions
- Primary Open Angle Glaucoma
- Interventions
- Drug: TGF-β2 antisense oligonucleotideProcedure: Trabeculectomy
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 13
- Registration Number
- NCT02406833
- Locations
- 🇩🇪
University Hospital Magdeburg, Ophthalmology, Magdeburg, Germany
🇩🇪Department of Ophthalmology, Johannes-Gutenberg University Mainz, Mainz, Germany
🇩🇪University of Tuebingen, Center of Ophthalmology, Tuebingen, Germany
Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2
- Conditions
- MelanomaColorectal NeoplasmsPancreatic Neoplasms
- Interventions
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 62
- Registration Number
- NCT00844064
- Locations
- 🇩🇪
Universitätsmedizin Berlin Charité, Berlin, Germany
🇩🇪Universitätsklinik und Poliklinik für Innere Medizin I, Halle (Saale), Germany
🇩🇪Hautklinik der Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
- Conditions
- Anaplastic AstrocytomaGlioblastoma
- Interventions
- Device: Drug delivery system for administration of AP 12009Procedure: Placement of Drug Delivery System
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 27
- Registration Number
- NCT00761280
- Locations
- 🇺🇸
NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸Winthrop University Hospital, Mineola, New York, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma
- Conditions
- GlioblastomaAnaplastic Astrocytoma
- Interventions
- Device: Drug delivery system for administration of AP 12009Procedure: Placement of Drug Delivery System
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2013-12-03
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 141
- Registration Number
- NCT00431561
- Locations
- 🇦🇹
Universitätsklinik Innsbruck; Abteilung für Neurochirurgie, Innsbruck, Austria
🇦🇹Landes-Nervenklinik Wagner-Jauregg, Linz, Austria
🇦🇹Kaiser Franz Josef Spital, Abteilung für Neurologie, Wien, Austria